Overview

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Status:
Terminated

Trial end date:
2017-09-21

Target enrollment:

Participant gender:

Summary

This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.

Phase:

Phase 2

Details

Lead Sponsor:

US Oncology Research

Collaborator:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma